The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Open accessAbstract
Cancer therapy by entrapment: Mutations in the KRAS oncogene occur at high frequency in several of the most lethal human cancers, including lung and pancreatic cancer. Substantial effort has thus been directed toward developing KRAS inhibitors. KRAS encodes an enzyme that binds the nucleotide GTP and hydrolyzes it to GDP. It had been thought that oncogenic mutations disable this hydrolytic activity, locking KRAS in the GTP-bound, active state. Surprisingly, Lito et al. found that a certain KRAS mutant (G12C) retains hydrolytic activity and continues to cycle between its active and inactive states. They describe a compound that inhibits KRAS(G12C) signaling and tumor cell growth by binding to the GDPbound form of KRAS, trapping it in its inactive state. Science , this issue p. 604
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“early preclinical studies with KRASG12C inhibitors, such as ARS-1620, have suggested a potential role for adaptive feedback as a mechanism of resistance (7) (15).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, as described by Lito et al, increased RTK activity may lead to increased cycling of KRASG12C to its active GTP-bound form that hinders the binding of most KRASG12C inhibitors, which bind specifically to the inactive GDP-bound form (7).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“compounds have been identified that bind covalently to cysteine 12 within the switch II pocket of the GDP-bound form of the KRASG12C protein, preventing oncogenic signaling and causing potent tumor regressions in preclinical models.3-7”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, the appreciable degree of nucleotide cycling observed in KRAS G12C -mutant protein proved critical for the development of clinically active KRAS G12C -selective inhibitors which bind the GDP-bound conformation and lock KRAS in the inactive state [7-9].”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies have identified EGFR as a major mediator of adaptive feedback, and concomitant blockade of EGFR has been shown to enhance the antitumor activity of KRAS G12C inhibition12,15.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [15]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“The inhibitors function by locking KRASG12C in an inactive GDP bound state, exploiting the unique property of KRASG12C to cycle between the GDP- and GTP-bound states (6,7).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“These resistance mutations probably increase the fraction of KRAS protein in the active GTP-bound form that does not bind to the drug.4”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Preclinical studies have identified EGFR as a major mediator of adaptive feedback, and concomitant blockade of EGFR has been shown to enhance the antitumor activity of KRAS G12C inhibition12,15.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Given this particular feature of the KRAS G12C mutant protein, the efficacy of these compounds can be increased by concomitant receptor tyrosine kinase (RTK) inhibition that further maintain KRAS G12C in a GDP-bound conformation, facilitating the binding of the covalent inhibitor(7-9).”
From EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. (2020) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“It is known that RTK inhibition in NSCLC preclinical models can potentiate KRAS G12C covalent inhibitors, by slowing down exchange factors favoring a GDP-bound status of KRAS(8).”
From EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. (2020) · cites this paper as [8]
In the citing paper
“ARS-853 was firstly selected as a potent inhibitor that suppresses K-RasG12C-dependent cell proliferation.4,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“The binding of these compounds to K-RasG12C induces structurally disordered switch I/II, which converts the GTP preference of naive K-RasG12C to GDP.”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“However, it failed to demonstrate in vivo efficacy due to undesirable pharmacokinetics.4,5,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“Consequently, a large fraction of K-RasG12C protein is trapped in the inactive GDP-bound state, which impairs its interaction with downstream effectors, such as rapidly accelerated fibrosarcoma kinase (RAF).3,4,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“For example, secondary KRAS mutations would confer intrinsic resistance to ARS-853 in KRASG12C mutant models by either potentiating nucleotide exchange (secondary mutation: Y40A, N116H, or A146V) or impairing inherent GTPase activity (secondary mutation: A59G, Q61L, or Y64A) (Figure 3D).49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“Instead, K-RasG12C inhibitors act primarily through targeting MAPK/ERK pathway for growth inhibition.4, 5, 6, 7,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“These preclinical findings strongly imply that intrinsic resistance might be accountable for the heterogeneous responses to K-RasG12C inhibition in the clinic.4, 5, 6, 7,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“In most KRASG12C mutant models, the phosphorylation status of AKT and mTORC1-effector ribosomal protein S6 is barely affected by K-RasG12C inhibition.6,7,12,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“In line with the these findings, inconsistent results were observed co-treating KRASG12C mutant cancer cells with K-RasG12C inhibitors plus either MEK or ERK inhibitors, limiting the use of these drug combinations in the clinic.6,12,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“Lito et al.49 reported that the effect of ARS-853 was potentiated by EGFR inhibition in H2122 and Calu-1 cells.”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“improvements in drug design have culminated in the development of inhibitors that are selective for mutant KRAS in its active or inactive state.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [65]
In the citing paper
“Accordingly, inhibitors of this type are KRASG12C specific; therefore, they do not affect RAS signalling in non-malignant cells65,70–72 and, at least theoretically, have a low risk of on-target, off-tumour toxicities.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [65]
In the citing paper
“KRASG12C is not permanently GTP-bound and maintains a dependency on upstream receptor tyrosine kinase (RTK) signaling for GEF-mediated GTP reloading (9, 10).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [9]
In the citing paper
“The rationale for pursuing SHP2 and SOS1 inhibitors as pan-KRAS inhibitors is grounded in the evidence that several (K)RAS oncoproteins, including KRASG12C, still cycle between an inactive and active state and rely on upstream activation and nucleotide exchange to exhibit their full transforming potential (9–13, 33, 34).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [9]
In the citing paper
“G12C-Is bind an evanescent pocket in KRAS-GDP, positioning a reactive group to couple to the mutant cysteine.”
From SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling (2021) · cites this paper as Lito et al., 2016
In the citing paper
“follow-up studies indicated that these initial compounds showed only limited potency (39, 40).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [39]
In the citing paper
“Binding of compound 12 to the switch II pocket impaired KRAS signalling by shifting nucleotide affinity from favouring GTP to GDP and led to the accumulation of KRAS in its inactive state91.”
From Advances in covalent drug discovery (2022) · cites this paper as [91]
In the citing paper
“Still, the mutant KRAS undergoes GDP–GTP cycling [5].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Niesen, F., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,420
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
GEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1128/MCB.8.6.2472 · DOI
Cited by
Sorted by citations
Items 401–500 of 700
Wang, P., van der Hoeven, D., Ye, N., Chen, H., Liu, Z., Ma, X., Montufar‐Solis, D., Rehl, K. M., Cho, K., Thapa, S., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113381 · Cited by 12
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
Arbour, K. C., Manchado, E., Bott, M. J., Ahn, L. S. H., Tobi, Y. Y., Ni, A. A., Yu, H. A., Shannon, A., Ladanyi, M., Perron, V., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100256 · Cited by 13
Self-citationHan, Z., Zhou, D., Wang, J., Jiang, B., & Liu, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188677 · Cited by 13
Spagnuolo, A., Maione, P., & Gridelli, C. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-948 · Cited by 15
Identification of lysine methylation in the core GTPase domain by GoMADScan
Yoshino, H., Yin, G., Kawaguchi, R. K., Popov, K. I., Temple, B. R. S., Sasaki, M., Kofuji, S., Wolfe, K., Kofuji, K., Okumura, K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219436 · Cited by 13
Synthetic Vulnerabilities in the KRAS Pathway
Román, M., Hwang, E. E., & Sweet-Cordero, A. (2022) · Cancers · doi:10.3390/cancers14122837 · Cited by 14
Herzberg, B. O., & Manji, G. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad014 · Cited by 15
GLOBAL AND TARGETED PROFILING OF GTP‐BINDING PROTEINS IN BIOLOGICAL SAMPLES BY MASS SPECTROMETRY
Huang, M., & Wang, Y. (2020) · Mass Spectrometry Reviews · doi:10.1002/mas.21637 · Cited by 12
Qian, J., Li, Z., Pei, K., Li, Z., Li, C., Yan, M., Qian, M., Song, Y., Zhang, H., & He, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.712484 · Cited by 14
Park, M. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115906 · Cited by 13
Liu, Q., Chen, J., Fu, B., Dai, J., Zhao, Y., & Lai, L. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.038 · Cited by 12
Mechanisms of resistance to active state selective tri-complex RAS inhibitorsPreprint
Sang, B., Ye, L. F., Hu, F., Pourfarjam, Y., Cuevas-Navarro, A., Fan, S., Fu, Z. Q., Washington, A., Rodriguez, D. J., Vides, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.24.649345 · Cited by 12
Self-citationMolecular docking analysis of KRAS inhibitors for cancer management
Alam, Q. (2023) · Bioinformation · doi:10.6026/97320630019411 · Cited by 11
KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner
Laurent, P.-A., Milić, M., Quevrin, C., Meziani, L., Liu, W., Morel, D., Signolle, N., Clémenson, C., Lévy, A., Mondini, M., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04619-0 · Cited by 12
Resistance to KRAS inhibition in advanced non-small cell lung cancer
Sreter, K. B., Catarata, M. J., von Laffert, M., & Frille, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357898 · Cited by 12
Zhou, Q. H., Yang, N., Zhao, M., Huang, D., Zhao, J., Yu, Y., Yuan, Y., Sun, L., Dong, X., Zhang, T., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114337 · Cited by 11
An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors
Hansen, R., Firdaus, S. J., Li, S., Janes, M. R., Zhang, J., Liu, Y., & Zarrinkar, P. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-32683-w · Cited by 10
Self-citationRas inhibition by zoledronic acid effectively sensitizes cervical cancer to chemotherapy
Xu, J., Pan, Q., & Ju, W. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000779 · Cited by 11
Recapitulation of cell-like KRAS4b membrane dynamics on complex biomimetic membranes
Shrestha, R., Chen, D., Frank, P. H., Nissley, D. V., & Turbyville, T. J. (2021) · iScience · doi:10.1016/j.isci.2021.103608 · Cited by 11
Issahaku, A. R., Salifu, E. Y., & Soliman, M. E. S. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2074141 · Cited by 13
Kwon, J. J., Dilly, J., Liu, S., Kim, E., Bian, Y., Dharmaiah, S., Tran, T. H., Kapner, K. S., Ly, S. H., Yang, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.22.618529 · Cited by 13
Murciano-Goroff, Y. R., Hollebecque, A., Heist, R. S., Cassier, P. A., Han, J.-Y., Kim, S. Y., Sabari, J. K., Tosi, D., Sacher, A., Burns, T. F., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69943-7 · Cited by 13
Hoang, T. T., Tanrikulu, I. C., Vatland, Q. A., Hoang, T. M., & Raines, R. T. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0724 · Cited by 10
Early-stage structure-based drug discovery for small GTPases by NMR spectroscopy
Yin, G., Lv, G., Zhang, J., Jiang, H., Lai, T., Yang, Y., Ren, Y., Wang, J., Yi, C., Chen, H., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108110 · Cited by 11
Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development
Ranđelović, I., Nyíri, K., Koppány, G., Baranyi, M., Tóvári, J., Kigyós, A., Tímár, J., Vértessy, B. G., & Grolmusz, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052572 · Cited by 10
DNA encoded peptide library for SARS-CoV-2 3CL protease covalent inhibitor discovery and profiling
Xing, Y., Zhang, H., Wang, Y., Zong, Z., Bogyo, M. S., & Chen, S. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00097h · Cited by 10
Su, L., Wang, D., Purwin, T. J., Ran, S., Yang, Q., Zhang, Q., & Cai, W. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.03.021 · Cited by 10
Sotorasib – an inhibitor of KRAS p.G12c mutation in advanced non-small cell carcinoma
Agrawal, A. K., Pragya, R., Choudhary, A., Gupta, A. K., Sambasivaiah, K., Mishra, B. K., Khaddar, S., & Kapoor, A. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_145_21 · Cited by 10
Niitsu, Y., Sato, Y., & Takayama, T. (2022) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.98.005 · Cited by 11
Probing the KRas Switch II Groove by Fluorine NMR Spectroscopy
Peacock, D. M., Kelly, M. J. S., & Shokat, K. M. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00566 · Cited by 8
Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors
Arbour, K. C., & Lito, P. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00562 · Cited by 10
Self-citationGao, L., & Shen, W. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.890247 · Cited by 11
Shin, W., Lee, S.-K., Hwang, J.-H., Park, J.-C., Cho, Y.-H., Ro, E. J., Song, Y., Seo, H. R., & Choi, K.-Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0102-5 · Cited by 10
Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells
Lee, C., Yi, J., Park, J., Ahn, B., Won, Y.-W., Jeon, J., Lee, B. J., Cho, W. J., & Park, J. W. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06436-9 · Cited by 9
Jiang, Z., Li, Y., Zhou, X., Wen, J., Zheng, P., & Zhu, W. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117627 · Cited by 9
Ferrarone, J. R., Thomas, J., Unni, A. M., Zheng, Y., Nagiec, M. J., Gardner, E. E., Mashadova, O., Li, K., Koundouros, N., Montalbano, A., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2403685121 · Cited by 10
Wang, X., Breuer, J., Garbe, S., Giordano, F. A., Brossart, P., Feldmann, G., & Bisht, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116249 · Cited by 10
Péczka, N., Ranđelović, I., Orgován, Z., Csorba, N., Egyed, A., Petri, L., Ábrányi‐Balogh, P., Gadanecz, M., Perczel, A., Tóvári, J., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00217 · Cited by 10
Chen, K., Okamura, Y., Hatakeyama, K., Shiomi, A., Kagawa, H., Hino, H., Manabe, S., Yamaoka, Y., Sugiura, T., Sugino, T., et al. (2024) · Surgery Today · doi:10.1007/s00595-024-02900-3 · Cited by 9
Emerging opportunities for intact and native protein analysis using chemical proteomics
Edwards, A. N., & Hsu, K. (2024) · Analytica Chimica Acta · doi:10.1016/j.aca.2024.343551 · Cited by 11
Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer
Deming, D. A. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7067 · Cited by 12
Wang, P., Sun, X., He, X., Kang, D., Liu, X., Liu, D., Li, A., Yang, G., Lin, Y., Li, S., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0001 · Cited by 9
Denitrogenative Alkylation of K-Ras(G12D) Inhibits Oncogenic Signaling in Cancer Cells
Zheng, Q., & Shokat, K. M. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c06745 · Cited by 9
Ebrahimi, S., Lohnes, B. J., Khan, S. A., Peipp, M., Bockamp, E., Klein, C., Abken, H., Wölfel, C., Theobald, M., & Hartwig, U. F. (2025) · Journal of Molecular Medicine · doi:10.1007/s00109-025-02585-2 · Cited by 9
Biomolecular Condensates as Protein Degradation Tools for Intracellular Targets
Li, Y., Jin, Z., Ahmed, S. U., Das, J., Bleher, R., Chang, D., Yu, X., Flynn, C. D., Zhou, J., Hu, X., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72967-8 · Cited by 11
Wang, Y., He, M., Li, X., Chai, J., Jiang, Q., Peng, C. Y., He, G., & Huang, W. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.700956 · Cited by 9
AZD4625 is a Potent and Selective Inhibitor of KRASG12C
Chakraborty, A., Hanson, L. L., Robinson, D. M., Lewis, H. J., Bickerton, S., Davies, M., Polański, R., Whiteley, R., Koers, A., Atkinson, J. M., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0241 · Cited by 9
Luo, W. P., Zhu, J., Zhang, W., Yu, A., Zhou, W., & Xu, K. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2282606 · Cited by 10
Let K-Ras activate its own inhibitor
Statsyuk, A. V. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0066-0 · Cited by 9
Small Molecule Imaging Agent for Mutant KRAS G12C
Koch, P. D., Quintana, J. M., Ahmed, M. S., Köhler, R. H., & Weissleder, R. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000290 · Cited by 9
Colorectal cancer-derived exosomes and modulation KRAS signaling
Wan, Y. H., Liu, Q. S., Wan, S. S., & Wang, R. W. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02877-w · Cited by 9
Adagrasib: a novel inhibitor for KRAS G12C -mutated non-small-cell lung cancer
Guo, M. Z., Marrone, K. A., Spira, A. I., & Rosner, S. (2023) · Future Oncology · doi:10.2217/fon-2022-1106 · Cited by 10
RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming
Miller‐Phillips, L., & Collisson, E. A. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01096-x · Cited by 10
Park, R., Al‐Jumayli, M., Miller, K. A., Saeed, A., & Saeed, A. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100342 · Cited by 9
Mues, M., & Roose, J. P. (2016) · Small GTPases · doi:10.1080/21541248.2016.1187323 · Cited by 9
Towards functional maps of non-coding variants in cancer
Wang, Y., & Hon, G. C. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1481443 · Cited by 8
Top advances in lung cancer, 2021
Mohindra, N. A., & Patel, J. D. (2022) · Cancer · doi:10.1002/cncr.34406 · Cited by 8
2′-Deoxy Guanosine Nucleotides Alter the Biochemical Properties of Ras
Yun, S. D., Scott, E., Moghadamchargari, Z., & Laganowsky, A. D. (2023) · Biochemistry · doi:10.1021/acs.biochem.3c00258 · Cited by 9
Zhao, Q., Haga, R., Tamura, S., Shimada, I., & Nishida, N. (2023) · Scientific Reports · doi:10.1038/s41598-023-46623-w · Cited by 9
The RASSF1A Tumor Suppressor Binds the RasGAP DAB2IP and Modulates RAS Activation in Lung Cancer
Stewart, D. R. H., Schmidt, M., Donninger, H., & Clark, G. J. (2020) · Cancers · doi:10.3390/cancers12123807 · Cited by 8
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
Kulshrestha, R., Kumar, P., Singh, A., Nupur, K., Spalgias, S., Mrigpuri, P., & Rajkumar (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00061-0 · Cited by 8
Bum‐Erdene, K., Ghozayel, M. K., Xu, D. D., & Meroueh, S. O. (2022) · ChemMedChem · doi:10.1002/cmdc.202100750 · Cited by 8
Gorachinov, F., Mraiche, F., Moustafa, D. A., Hishari, O., Ismail, Y., Joseph, J. M., Crcarevska, M. S., Dodov, M. G., Geškovski, N., & Goračinova, K. (2023) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.14.23 · Cited by 8
Sharma, N., Sonavane, U., & Joshi, R. (2017) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2017.05.008 · Cited by 8
Tisi, R., Spinelli, M., Palmioli, A., Airoldi, C., Cazzaniga, P., Besozzi, D., Nobile, M. S., Mazzoleni, E., Arnhold, S., GIOIA, L. D., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.625979 · Cited by 8
A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and TargetsPreprint
Chen, H., Bird, R. E., Wang, D.-S., Diaz, L. M. L., Iyer, K. A., Gustafson, G. R., Kato-Weinstein, J., & Zhou, Q. A. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-wf79n-v2 · Cited by 8
Shi, J.-T., Hou, S.-J., Cheng, L., Zhang, H., Mu, H.-X., Wang, Q., Wang, Z., & Chen, S. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107467 · Cited by 7
Posttranslational modifications remodel proteome-wide ligandability
Li, W., Wei, Q., Llanos, M. A., Gathmann, C., Governa, P., Chiu, T.-Y., Wozniak, J. M., Jadhav, A. M., Holcomb, M., Cravatt, J. B., et al. (2026) · Nature Chemical Biology · doi:10.1038/s41589-026-02216-y · Cited by 9
Optimizing KRAS Therapeutics for Non–Small Cell Lung Cancer
Lim, J. U., Negrao, M. V., & Hong, D. S. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-115849 · Cited by 9
Identification and characterization of binders to a cryptic and functional pocket in KRAS
Beyer, K. S., Klein, J., Katz, S., Welker, P., Lanter, M., Guthy, D. A., Pollehn, K., Gluck-Gadé, A., Bleu, M., Desogus, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65844-3 · Cited by 7
Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C
Endres, N., Do, S., Mroue, R. M., Terrett, J. A., Saabye, M., Oh, A., Hunsaker, T., Chan, E., (1471192), J. C. T., Nguyen, L. K., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02272 · Cited by 8
Stahlhut, C. E., Maciag, A. E., Sullivan, K. A., Singh, K., Gitego, N., Zhang, Z., Chan, A. H., Sharma, A. K., Alexander, P., Shu, J., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1280 · Cited by 10
Li, N., Liu, C., Zhang, W., & Rao, G. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673258913231019113814 · Cited by 7
Discovery of LHF418 as a new potent SOS1 PROTAC degrader
Li, H., Chai, M., Chen, Y., Zhou, F., Ren, X., Xu, J., Wang, J., Wang, Z., & Huang, W. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117661 · Cited by 7
Crystal structure of NRAS Q61K with a ligand-induced pocket near switch II
Gebregiworgis, T., Chan, J. Y.-L., Kuntz, D. A., Privé, G. G., Marshall, C. B., & Ikura, M. (2024) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2024.151414 · Cited by 10
The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors
Kareff, S. A., Trabolsi, A., Krause, H. B., Samec, T., Elliott, A., Rodríguez, E., Olazagasti, C., Watson, D. C., Bustos, M. A., Hoon, D. S. �., et al. (2024) · Cancers · doi:10.3390/cancers16081572 · Cited by 7
Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer
Novoplansky, O., Jagadeeshan, S., Prasad, M., Yegodayev, K. M., Marripati, D., Shareb, R. A., Greenshpan, Y., Mathukkada, S., Lulu, T. B., Bhattacharya, B., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03227-0 · Cited by 8
A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling
Kauke, M. J., Tisdale, A. W., Kelly, R. L., Braun, C. J., Hemann, M. T., & Wittrup, K. D. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0645 · Cited by 8
Overview of Current Immunotherapies Targeting Mutated KRAS Cancers
Hoo, W. P. Y., Siak, P. Y., & In, L. L. A. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190904163524 · Cited by 7
Batra, U., & Nathany, S. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_189_21 · Cited by 7
Sankarasubramanian, S., Pfohl, U., Regenbrecht, C. R. A., Reinhard, C., & Wedeken, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.760705 · Cited by 7
An In Vivo Inflammatory Loop Potentiates KRAS Blockade
Arendt, K. A. M., Ntaliarda, G., Armenis, V., Kati, D., Henning, C., Giotopoulou, G. A., Pepe, M. A. A., Klotz, L. V., Lamort, A., Hatz, R. A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10030592 · Cited by 7
The KRYSTAL-1 study of adagrasib — a new trial for KRASG12C-mutated non-small-cell lung cancer
Murciano‐Goroff, Y. R., & Lito, P. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00676-4 · Cited by 8
Self-citationPutting the brakes on KRAS-G12C nucleotide cycling
Shipman, L. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.40 · Cited by 7
Pang, X., & Liu, M. (2016) · 癌症：英文版 · doi:10.1186/s40880-016-0154-7 · Cited by 7
Nichols, R. J., Haderk, F., Stahlhut, C. E., Schulze, C. J., Hemmati, G., Wildes, D. P., Tzitzilonis, C., Mordec, K., Marquez, A., Romero, J. M., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/188730 · Cited by 7
SRC at the Crossroads of KRAS Inhibitor Resistance: Mechanisms and Therapeutic Opportunities
Tian, H., Zhao, D., Zhou, Z., Kim, A., Huang, H., Lee, Y. J., Qu, Z., Kang, R., Zeh, H. J., Westover, K. D., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2025.218194 · Cited by 7
Unlocking the Molecular Targets in Non-Small-Cell Lung Cancer and a Nanomedicine-Based Remedy
Sarma, K., Akhter, M. H., Alalmaie, A., Ahmad, I., Ansari, M. N., Khalilullah, H., Farhana, S. A., Hussain, S. M., & Aljadaan, A. M. (2025) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2024053289 · Cited by 6
Trogdon, M., Abbott, K. L., Arang, N., Lande, K., Kaur, N., Tong, M. M., Bakhoum, M. F., Gutkind, J. S., & Stites, E. C. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00400-1 · Cited by 7
Warnecke, B., & Nagasaka, M. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s466217 · Cited by 7
Synthetic approaches and clinical application of KRAS inhibitors for cancer therapy
Jiang, M., Ma, S., Xuan, Y., & Chen, K. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117626 · Cited by 6
Ras proteins as therapeutic targets
Chakraborty, A., Linnane, E., & Ross, S. J. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170529 · Cited by 6
Quest for Clinically Effective RAF Dimer Inhibitors
Xue, J. Y., & Lito, P. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00401 · Cited by 6
Self-citationbioPROTACs establish RAS as a degradable target and provide novel RAS biology insightsPreprint
Lim, S., Khoo, R., Juang, Y.-C. A., Gopal, P., Zhang, H., Yeo, C., Peh, K. M., Teo, J., Ng, S., Henry, B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.26.174565 · Cited by 6
Sharma, N., Sonavane, U., & Joshi, R. (2020) · PLOS ONE · doi:10.1371/journal.pone.0234836 · Cited by 7
Regulation of nucleotide excision repair by wild-type HRAS signaling in head and neck cancer
Hoxhallari, L., Katsikis, K., Makri, A., Pouliou, M., Kanaki, Z., Vatsellas, G., Sonou, C., Telios, D., Giotakis, E. I., Giotakis, A. Ι., et al. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00902-y · Cited by 5
Huang, R., Gong, X., Du, J., Xu, G., Qian, J., Liao, G., Lin, Y., Pan, M., Zheng, B., Yuan, W., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1704347 · Cited by 6
Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics
Grochot, R. M., Bartolini, M., Algaze, S. D., Reimann, P., Winder, T., Lenz, H., & Fontana, E. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-516576 · Cited by 5
McAndrews, K. M., Mahadevan, K. K., Li, B., Comptdaer, A. M., Sockwell, A. M., Morse, S. J., Kelly, P. J., Patel, S. I., Kirtley, M. L., Diaz, B. A. M., et al. (2026) · The EMBO Journal · doi:10.1038/s44318-026-00854-5 · Cited by 10
Hussain, J., Chhabria, D., & Kirubakaran, S. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127290 · Cited by 5
Metadata
- Authors
- Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Wellspring Biosciences (United States) (US)
- Corresponding author
- Lito, Piro
- Rosen, Neal
- Venue
- Science
- Published
- 2016-02-05
- Volume
- 351
- Issue
- 6273
- Pages
- 604-608
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4955282
- OpenAlex
- W2233032895
- Semantic Scholar
- e165d3c03cf60d1cdc247a235e53363d62727803
- Cited by
- 691
- References
- 38
- Citations by year
- 2026: 53 · 2025: 62 · 2024: 69 · 2023: 75 · 2022: 86 · 2021: 92 · 2020: 71 · 2019: 58 · 2018: 47 · 2017: 49 · 2016: 29
- FWCI
- 31.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (P01CA129243-06, K08CA191082-01A1)
- Memorial Sloan Kettering Cancer Center Experimental Therapeutics (SKI12103)
- LUNGevity Foundation Career Development Award
- V Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- KRAS G12C, GTPase activity, nucleotide exchange, KRAS-driven cancers, tyrosine kinase signaling, tumor cell growth inhibition
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Alleles, Antineoplastic Agents, Azetidines, Cysteine, Cytidine Diphosphate, Enzyme Inhibitors, Glycine, Guanosine Triphosphate, Humans, Lung Neoplasms, Mutation, Piperazines, Protein Conformation, Time Factors, Proto-Oncogene Proteins p21(ras), Cell Line, Tumor, HEK293 Cells, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
